Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06659952 · ClinicalTrials.gov registry record · NA

HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients

A NA study of HIV Infection and Advanced End Stage Heart Failure, sponsored by University of Texas Southwestern Medical Center.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT06659952: Recruiting NA study of HIV Infection and Advanced End Stage Heart Failure, sponsored by University of Texas Southwestern Medical Center.

NCT06659952 is a NA study of HIV Infection and Advanced End Stage Heart Failure that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 50 participants, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06659952, a NA study of HIV Infection and Advanced End Stage Heart Failure, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This will be a prospective single-center interventional trial to compare the outcomes of HIV-positive heart transplant recipients by the HIV status of the donor; HIV-positive vs. HIV-negative and learn whether heart organ transplantation from HIV+ deceased donors is as safe and effective in HIV+ recipients as transplants from HIV- deceased donors. Patient will undergo standard evaluation for eligibility of transplantation by the primary heart transplant team. If patient meets eligibility criteria, they will be informed about the study and consent will be obtained. Informed consent will be obtained in a private clinic or inpatient hospital room in a confidential setting. HIV-positive or HIV-negative offers will be made by Organ Procurement and Transplantation Network (OPTN) (serving as a means of "natural randomization" and this information will also be collected, along with the information regarding any information for primary offer declines from the patients as well as other clinical indications to decline an organ offer. As a result of this, there will be two main groups in the study participants that will undergo analysis: 1. patients/recipients that are HIV+ who receive an organ from an HIV+ donor (HIV D+/R+ group) 2. patients/recipients that are HIV+ who receive an organ from an HIV negative donor (HIV D-/R+ group) Only study participants will be able to receive organ offers from both HIV-positive and HIV-negative organ donors whichever is available first regardless of HIV status. This is the only study intervention. Baseline visit parameters will be obtained during a routine heart transplant visit. There will be no additional procedures or blood collection after the baseline study visit. Study data will be collected from chart review of routine post-transplant follow-up visits at weeks 52 (1 year), 104 (2 years), and 152 (3 years) after the transplant.

Primary Outcome

Time to event outcome measured as the time from randomization to the occurrence of the first event.

Interventions

  • OTHER HIV-positive heart transplant

Study Locations (1)

Texas

  • UT Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-11-13
Est. Completion 2034-10
Phase NA

What NCT06659952 shows while recruiting

NCT06659952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (79% lower).

The record links to 2 conditions, with HIV Infection appearing as the primary indexed condition, and to 1 intervention - of which HIV-positive heart transplant is the first listed.

NCT06659952 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06659952 about?

NCT06659952 is a clinical study titled "HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients". This will be a prospective single-center interventional trial to compare the outcomes of HIV-positive heart transplant recipients by the HIV status of the donor; HIV-positive vs. HIV-negative and learn whether heart organ transplantation from HIV+ deceased donors is as safe and effective in HIV+ rec...

What is the current status of trial NCT06659952?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2024-11-13. Estimated completion is 2034-10.

What conditions does trial NCT06659952 study?

This clinical trial studies the following conditions: HIV Infection, Advanced End Stage Heart Failure.

What interventions are being tested in trial NCT06659952?

The interventions under investigation include: HIV-positive heart transplant (OTHER).

Who is sponsoring clinical trial NCT06659952?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06659952 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06659952's enrollment target sits among peer trials

50 38th of 73 higher than 34 of 73 other HIV Infection trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06659952, the US trial registry maintained by the National Library of Medicine. NCT06659952 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.